INTRODUCTION
Pluripotent stem cells undergo progressive restriction in their lineage potential to give rise to mature terminally differentiated cells. Genetic manipulations, such as gene-knockout and genetransfer experiments, increasingly provide evidence that regulated transcription factor expression is involved directly in the execution of the differentiation programme. The role of a number of transcription factors in haematopoietic cell differentiation has been revealed by knockout studies in mice, which have identified GATA-1 and -2, Tal-1\SCL, Ikaros, c-Myb, AML-1 and PU.1 genes, among others, as key regulators of haematopoiesis (reviewed in [1, 2] ). Complementary ectopic expression studies have identified some transcription factors as master regulators of development. Accordingly, several haematopoietic disorders and leukaemia are associated with de-regulated activity of specific transcription factors [2] .
Several transcription factors are involved in the control of myeloid differentiation, including PU.1 of the Ets family, which affects multiple lineages of haematopoiesis at an early stage [3] , CCAAT-enhancer-binding protein (C\EBP) α and ε, which are involved in granulocytic maturation [4, 5] , and Egr-1, a zincfinger protein that drives macrophage differentiation [6] . Recently a key role has been demonstrated for a member of the interferon regulatory factor (IRF) family, IRF-8, in myeloid-cell lineage selection and macrophage maturation [7] .
Abbreviations used : IRF, interferon regulatory factor ; G-CSF, granulocytic colony-stimulating factor ; IL, interleukin ; HPC, human progenitor cell ; CAT, chloramphenicol acetyltransferase ; EMSA, electrophoretic mobility-shift assay ; NK, natural killer ; RT-PCR, reverse transcriptase PCR ; C/EBP, CCAAT-enhancer-binding protein. 1 To whom correspondence should be addressed (e-mail battist!iss.it).
deprivation differentiated fully to neutrophils. Moreover, in the presence of G-CSF, granulocytic differentiation of IRF-1-expressing cells was accelerated, as assessed by morphology and expression of specific differentiation markers. Down-modulation of c-Myb protein and direct stimulation of lysozyme promoter activity by IRF-1 were also observed. Conversely, constitutive expression of IRF-2, a repressor of IRF-1 transcriptional activity, completely abrogated the G-CSF-induced neutrophilic maturation. We conclude that IRF-1 exerts a pivotal role in granulocytic differentiation and that its induction by G-CSF represents a limiting step in the early events of differentiation.
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The nine cellular members of the IRF family possess a novel helix-turn-helix DNA-binding motif that recognizes the consensus sequence AANNGAA on target genes [8, 9] . Structurally the IRF family shares homology with the Myb oncoproteins ; the best-characterized member, c-Myb, regulates differentiation and proliferation in immature haematopoietic and lymphoid cells [10, 11] . IRF-1 and its functional antagonist IRF-2 are the bestcharacterized members of the family. Originally discovered as transcription factors that play a role in the regulation of the interferon-β gene, IRF-1 and IRF-2 were then recognized to be involved in the regulation of genes expressed during inflammation, immune responses, haematopoiesis, cell proliferation and differentiation [12, 13] . The role of these two factors in the control of cell growth and apoptosis, especially in fibroblasts and T-lymphocytes, has lead to the definition of IRF-1 as a tumoursuppressor gene and of IRF-2 as an oncogene.
Studies in knockout mice also implicated IRF-1 and IRF-2 in the regulation of various immune processes such as T-cell selection and maturation, as well as leukaemogenic development. Impairment in CD8 + cell maturation, defective Th1 responses associated with defects in macrophage production of interleukin (IL)-12 and maturation of natural killer (NK) cells have all been observed in immune cells from IRF-1 −/− mice [14] [15] [16] [17] [18] .
Intensive functional analysis of IRF-1 has revealed a remarkable functional diversity of this transcription factor in the regulation of cellular responses. IRF-1 may function as a tumour suppressor by preventing the development of some forms of leukaemia and can specifically associate with IRF-8\ICSBP (interferon consensus sequence-binding protein), which was recently recognized as an essential component in macrophage maturation [7] . IRF-8 also inhibits granulocytic differentiation, which raises the possibility that interaction with IRF-1 may play a role in regulating pathways affecting lineage commitment and myeloid cell differentiation. To explore this possibility, we investigated the role of IRF-1 in granulocytic differentiation by introducing IRF-1 into murine myeloid progenitor 32Dcl3 cells. When grown in IL-3, these cells maintain the potential for monocytic differentiation, whereas treatment with granulocytic colony-stimulating factor (G-CSF) induces differentiation into granulocytes in i o [19] . We demonstrate that cells overexpressing IRF-1 do not become growth-factor-independent, but that a small percentage of cells surviving growth-factor deprivation spontaneously differentiate into mature neutrophils, as assessed by the expression of neutrophil-specific genes. Forced IRF-1 expression accelerated differentiation, whereas constitutive expression of its functional antagonist, IRF-2, completely abolished G-CSF-induced neutrophil differentiation. Interestingly, clear stimulation of IRF-1 expression was also observed in normal human progenitor CD34 + cells induced to differentiate along the granulocytic pathway. These results indicate that IRF-1 plays an indispensable role in granulocyte differentiation. DNA-binding activity and direct induction of the lysozyme promoter in co-transfection experiments suggest that IRF-1, at least in part, regulates genes involved in myeloid differentiation through its transcriptional activity.
MATERIALS AND METHODS

Cells and culture
32Dcl3 cells were grown in Iscove's modified Dulbecco's medium supplemented with 15 % heat-inactivated fetal calf serum and 2 ng\ml recombinant murine IL-3. Cells were cultured at 32 mC in a 5 % CO # atmosphere with twice-weekly passages at low cell density. For induction of terminal myeloid differentiation, cells were resuspended in medium containing 1000 units\ml recombinant murine G-CSF. To determine morphology, cells were spread on glass slides, fixed and stained with Wright's stain in methanol (Fisher, Pittsburgh, PA, U.S.A.) for 1 min, followed by the addition of an equal volume of 3 mM phosphate buffer, pH 6.8, for 2 min. Slides were then air-dried and examined by light microscopy at a magnification of i600. Morphological differences were determined using standard criteria as described previously [19] . All cell lines were negative for mycoplasma (Mycotest, Life Technologies).
Human progenitor cell (HPC) purification and differentiation
HPCs were purified according to Gabbianelli et al. [20] from adult peripheral blood, which was obtained from healthy donors after informed consent. Purified human haematopoietic progenitor cells were grown in serum-free medium containing BSA (10 mg\ml), pure human transferrin (1 mg\ml), human lowdensity lipoproteins (40 µg\ml), insulin (10 µg\ml), sodium pyruvate (10 −% M), -glutamine (2i10 −$ M), rare inorganic elements (Sn, Ni, Va, Mo and Mn) supplemented with iron sulphate (4i10 −) M) and nucleosides (10 µg\ml each). HPCs were induced into specific granulopoietic differentiation with IL-3 (1 unit\ml), granulocyte\monocyte CSF (0.1 ng\ml) and saturating amounts of G-CSF (500 units\ml).
RNA extraction and analysis
Total RNA was isolated by the guanidine\CsCl method [21] . RNase protection was performed on 5 µg of total RNA as described previously [22] . The 250 bp-long lactoferrin riboprobe was obtained by transcribing the plasmid pLF (a gift from Dr N. Berliner, Yale University School of Medicine, New Haven, CT, U.S.A.), linearized with StyI, with T3 polymerase. The plasmid pMCL 200 was obtained by cloning into the EcoRI and HindIII sites of pBluescript\KS a fragment of 200 bp excised with the same enzymes from the plasmid pMLC 1 (containing lysozyme cDNA, a generous gift from Dr R. Renkawitz, Justus-Liebig Universitat, Giessen, Germany). The riboprobe was prepared by transcribing the pMCL 200 plasmid linearized with HindIII using T7 polymerase.
To obtain the pBS IRF-1 construct, the plasmid pUC-IRF-1 (a generous gift from Dr T. Taniguchi, University of Tokyo Faculty of Medicine, Tokyo, Japan) was digested with SmaI and the 400 bp fragment cloned into the same site of pBluescript\KS (Stratagene). To generate the $#P-labelled 280 bp antisense IRF-1 RNA probe, the pBS IRF-1 plasmid was linearized with EcoRI and transcribed by T7 polymerase. An 18 S RNA probe was used as an internal standard to establish the relative amount of RNA loaded. tRNA was used as a control for the specificity of each riboprobe.
Reverse transcriptase PCR (RT-PCR) analysis
Total RNA was prepared and normalized as described in [23] . The normalized RNA was reverse-transcribed according to the manufacturer's instructions (Gibco-BRL, Gaithersburg, MD, U.S.A.). The RT-PCR was normalized for β2-microglobulin [23] (amplification within the linear range was achieved by 20 PCR cycles : denaturation at 95 mC for 30 s, annealing at 54 mC for 30 s and extension at 72 mC for 45 s). To evaluate expression of the IRF-1 gene, an aliquot of reverse-transcribed RNA (corresponding to $ 2 ng of RNA) was amplified within the linear range by 40 PCR cycles.
Each sample was electrophoresed in 2 % agarose, transferred to nylon membrane and hybridized with a specific probe. The following primers and probe were used : primer 5h, 5h-GTCCA-GCCGAGATGCTAAGAGC-3h ; primer 3h, 5h-GGCTGCCAC-TCCGACTGCTCC-3h ; probe, 5h-GGCCAAGAGGAAGTCA-TGTGGG-3h.
Transfection experiments
32Dcl3 cells were transfected by electroporation as described in [22] . For transfection experiments, the constructs p lys-0.5 CAT, RcCMV-IRF-1, RcCMV-IRF-2 and RcCMV were used. The p lys-0.5 CAT plasmid contained a 536 bp fragment of the murine lysozyme promoter (a generous gift from Dr R. Renkawitz) [24] . For the generation of stable transfectants, expression vectors for IRF-1 and IRF-2 (RcCMV-IRF-1 and RcCMV-IRF-2) were prepared as follows. To obtain the RcCMV-IRF-1 construct, the plasmid pUC-IRF-1 was digested with EcoRI, and the 2100 bplong fragment was subcloned into RcCMV (Invitrogen, San Diego, CA, U.S.A.). To generate the RcCMV-IRF-2 construct, the plasmid pHIRF4S-51 (a generous gift from Dr T. Taniguchi) was digested with XbaI-NotI and cloned into the same sites of RcCMV.
Transfection efficiency was normalized by assaying for β-galactosidase activity expressed from 0.5 µg of co-transfected RSV-β-gal plasmid [25] . All clones were frozen rapidly after identification and aliquots were periodically thawed (every 6-8 weeks) to maintain the identity of the clones. During that interval all phenomena described in this report (cell growth, IRF expression and G-CSF responsiveness) were stable and reproducible.
Enzymic assays
Determination of total chloramphenicol acetyltransferase (CAT) activity was performed as described previously [22] . 
Western-blot assay
Whole-cell extracts were prepared as described in [22] . Briefly, 20-50 µg of whole-cell extract was separated by SDS\PAGE (7.5 % or 10 % gels). Blots were incubated with polyclonal IRF-1 antibody (SC640 ; Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.), monoclonal kip1\p27 antibody (Transduction Laboratories, Lexington, KY, U.S.A.), monoclonal c-Myb antibody (type I ; UBI, Lake Placid, NY, U.S.A.) and PU.1 polyclonal antiserum (Santa Cruz Biotechnology), and then with anti-rabbit horseradish peroxidase-coupled secondary antibody (Amersham Pharmacia Biotech, Little Chalfont, Bucks, U.K.) using the enhanced chemiluminescence (ECL) system.
In vitro translation
Recombinant IRF-1 and IRF-2 were prepared by in itro translation in a reticulocyte lysate system (Promega TNT system) with T7 polymerase and plasmids in which the coding regions for IRF-1 or IRF-2 were downstream of the T7 promoter.
DNA electrophoretic mobility-shift assay (EMSA)
EMSA experiments were performed on total cell extracts as described previously [22] . Where indicated, 1 µl of anti IRF-1 or anti-IRF-2 [26] was added with 10 µg of cell extract to the reaction mixture. Analysis of DNA-protein complexes was carried out on 6 % polyacrylamide gels with 0.5iTBE [where 1iTBE is 50 mM Tris\borate (pH 8.2)\1 mM EDTA] as described previously [22] .
FACS analysis
The cells were stained with a FITC-conjugated anti-mouse CD11a, CD11b, CD11c or Gr-1 antibody (Pharmingen, San Diego, CA, U.S.A.) on ice for 30 min after blocking with a 100-fold excess of mouse IgG, and analysed on a FACScan flow cytometer (Becton Dickinson). FITC-conjugated rat IgG #a , rat IgG #b or hamster IgG " was used as isotype-matched negative controls.
RESULTS
Enhanced expression of IRF-1 during normal granulopoiesis and in G-CSF-induced 32Dcl3 cells
32Dcl3 cells constitute an interesting model to study granulocyte differentiation in itro. Although these murine myeloid progenitors are dependent on IL-3 for growth, when exposed to G-CSF, 32Dcl3 cells differentiate into mature granulocytes and closely mimic normal granulopoietic differentiation in the bone marrow [19] . Considering its role in tumour suppression and
Figure 1 IRF-1 induction by G-CSF
(A) Total RNA was extracted at the indicated times from 32Dcl3 cells treated with G-CSF (1000 units/ml) and analysed by RNase protection with a specific riboprobe for IRF-1 as described in the Materials and methods section. tRNA was included as an internal negative control for riboprobe specificity. The 18 S riboprobe was used as a control for RNA loading. A representative experiment from three performed is shown. (B) IRF-1 mRNA expression in purified HPCs and their progeny grown in liquid-phase granulopoietic culture was evaluated by semi-quantitative RT-PCR. A representative RT-PCR experiment from two independent sets of RNA is shown. β2-Microglobulin was used for normalization as indicated in the Materials and methods section.
growth arrest, we initially asked whether IRF-1 expression was modulated during myeloid differentiation. Total RNA, extracted from cells grown in IL-3 or treated for up to 4 days with recombinant G-CSF, were analysed by RNase protection with a specific riboprobe for IRF-1. As shown in Figure 1(A) , low-level expression of IRF-1 was observed in IL-3-proliferating 32Dcl3, whereas a 5-fold increase in IRF-1 expression was detected between 6 h and 96 h after induction of differentiation.
To investigate whether the observed IRF-1 up-regulation occurred during normal haematopoietic differentiation, purified human CD34 + progenitor cells were induced to differentiate along the neutrophilic pathway and IRF-1 expression was evaluated by RT-PCR. As shown in Figure 1 (B), purified CD34 + cells expressed low levels of IRF-1 on day 0, comparable with those present in 32Dcl3 cells grown in IL-3. However, beginning at day 2, a 15-fold increase in IRF-1 expression was observed ; this elevated level of expression remained constant throughout the differentiation process, including fully differentiated cells at day 14. At this time the majority of cells corresponded to neutrophils with segmented nuclei. These results indicate that IRF-1 was up-regulated at the transcriptional level during granulocytic differentiation and that 32Dcl3 cells mimic normal CD34 + progenitor cells in this regard.
IRF-1-expressing 32Dcl3 cells undergo granulocytic differentiation in the absence of G-CSF
To investigate the specific contribution of IRF-1 to neutrophilic differentiation, 32Dcl3 cells were selected that constitutively expressed IRF-1 : bulk populations were chosen to avoid clonal variability. After selection, transgene expression was assessed by immunoblot analysis (Figure 2A) . No IRF-1 expression was detectable in cells transfected with the empty RcCMV vector (32D\RcCMV), whereas clear expression of the human IRF-1 protein was seen in cells transfected with the RcCMV-IRF-1 construct. Although cell lines constitutively expressing IRF-1 have been difficult to establish in the past because of the apoptotic and growth-suppressive effects of IRF-1 [27] , we successfully selected stable IRF-1-expressing 32Dcl3 cells (32D\IRF-1 cells) . In Figure 2 . Total RNA (5 µg) was extracted from 32D/RcCMV and 32D/IRF-1 cells at the indicated times and analysed by RNase protection with specific riboprobes for lysozyme and lactoferrin as described in the Materials and methods section. tRNA was included as an internal negative control for riboprobe specificity. The 18 S riboprobe was used as a control for RNA loading. A representative experiment from three performed is shown.
Effect of ectopic IRF-1 expression on differentiation markers in growth-factor-deprived cultures
To analyse the characteristics of IRF-1-expressing cells, the expression of two membrane-differentiation markers and two genes specific for the early and late stages of granulocytic differentiation was evaluated at different time points in 32D\ RcCMV and 32D\IRF-1 cells deprived of growth factors. As shown in Figure 3(A) , no significant variations in the expression of CD11b and Gr-1, as assessed by flow cytometry in vectortransfected cells, were observed following growth-factor deprivation. In contrast, in IRF-1-expressing cells, a substantial stimulation was obtained. When Gr-1-positive cells were examined, 10-15 % of IRF-1-expressing cells were positive on day 0. After 4 days the percentage reached 30 %, a value that corresponded to that obtained in parental cells allowed to differentiate in G-CSF for 5 days (see Figure 4A in the next section). These results indicate that ectopic expression of IRF-1 is able to drive terminal granulocytic maturation of 32Dcl3 cells.
This conclusion was further reinforced by the analysis of lysozyme and lactoferrin mRNA expression : these are genes specific for the early and late stages of granulocytic differentiation, respectively [28] . As shown in Figure 3(B) , constant basal levels of lysozyme and lactoferrin mRNA were present in 32D\RcCMV cells ; conversely, in cells expressing IRF-1, lysozyme and lactoferrin mRNA levels increased, beginning 24 h after growth-factor-deprivation.
Effect of ectopic IRF-1 expression on G-CSF-induced granulocytic differentiation of 32Dcl3 cells
Since IRF-1 is rapidly induced by G-CSF in parental 32Dcl3 cells and exerts a direct effect on stimulation of differentiation markers, we asked whether constitutive IRF-1 expression could accelerate granulocytic differentiation. Parental 32Dcl3 cells, empty vector-transfected cells and IRF-1-expressing cells were allowed to differentiate in the presence of G-CSF and were analysed at different time points for the membrane expression of the myeloid markers CD11b and Gr-1, and for mRNA expression of lysozyme and lactoferrin. Flow-cytometry analysis of the Mac-1 (CD11b) marker revealed a 2-fold up-regulation as early as 3 days after treatment in IRF-1-expressing cells, indicating that IRF-1 overexpression accelerates the differentiation process. A slight increase in the Mac-1 expression in IRF-1-expressing cells as compared with the level obtained in parental and 32D\RcCMV cells, after 7 days of G-CSF, indicated that IRF-1 also improved cell differentiation ( Figure 4A ).
When the terminal granulocyte-differentiation marker Gr-1 was considered, IRF-1-expressing cells exhibited a 20 % positivity even in the presence of IL-3 (day 0), as shown in Figure 3 Analysis of lysozyme and lactoferrin mRNA expression (Figure 4B ) demonstrated an increase in the basal levels of lysozyme mRNA in parental cells at 48 h after G-CSF treatment. Maximal expression of lactoferrin was evident only at 72-96 h in fully differentiated cells ; 32D\RcCMV cells displayed a similar expression pattern. In contrast, in IRF-1-expressing cells the kinetics of expression for both markers were clearly accelerated and at 48 h the steady-state levels were increased 10-and 14-fold, respectively.
IRF-2-expressing cells are completely inhibited in G-CSF-induced granulocytic differentiation
To further demonstrate the direct effect of IRF-1 on neutrophilic differentiation, we also selected IRF-2-expressing clones. IRF-2 is known as the physiological transdominant negative of IRF-1
Figure 4 Differentiation characteristics of 32Dcl3 cells constitutively expressing IRF-1 and IRF-2 in the presence of G-CSF
(A) 32Dcl3 parental cells () and 32Dcl3 cells transfected with empty vector (#) or vectors expressing IRF-1 ($) and IRF-2 ( ) were induced to differentiate with G-CSF (1000 units/ml) for the indicated times. On each day the surface expression of CD11b and Gr-1 was assessed by flow cytometry. The results represent meanspS.E.M. from three independent experiments. (B) Expression of myeloid-specific genes in 32Dcl3 parental cells and cells transfected as in (A). Total RNA (5 µg) was extracted from cells treated for the indicated times with 1000 units/ml recombinant G-CSF and analysed by RNase protection with specific riboprobes as described in the Materials and methods section. tRNA was included as an internal negative control for riboprobe specificity. The 18 S probe was used as a control for RNA loading. A representative experiment of three performed is shown.
that competes with IRF-1 for binding to the same consensus DNA-binding sequence. As shown in Figure 4(A) , the membrane expression of CD11b and Gr-1 antigens was completely abolished by the constitutive expression of IRF-2, even in the presence of G-CSF. Lysozyme and lactoferrin mRNA expression was evaluated in IRF-2-expressing cells and confirmed the complete inhibition of granulocytic differentiation as a result of ectopic IRF-2 expression. In fact, no modulation of lysozyme mRNA levels was observed in IRF-2-expressing cells and a complete inhibition of the late differentiation marker lactoferrin was obtained ( Figure 4B ).
Mechanisms underlying the IRF-1 effect on granulocytic differentiation
Effect of IRF-1 on the growth rate of 32Dcl3 cells induced to differentiate
We next asked whether the increased differentiation of 32Dcl3 cells exerted by IRF-1 could be ascribed to alterations in the Interferon regulatory factor-1 potentiates granulocyte differentiation 
Figure 6 c-Myb and PU.1 modulation in 32D/RcCMV-and 32D/IRF-1-transfected cells
Total cell extracts from 32Dcl3 cells with the empty vector or the IRF-1-expressing vector were subjected to Western-blot analysis with anti-c-Myb and anti-PU.1 antibodies as described in the Materials and methods section. Cell extracts from Jurkat cells were used as a positive control for c-Myb expression.
growth rates of the IRF-1-expressing cells. Growth kinetic curves in the presence of G-CSF are shown for all the clones in Figure  5 . Parental cell cultures maintained in the presence of IL-3 grew exponentially, whereas in the presence of G-CSF cell growth decreased. The curves obtained in parental cells, in cells transfected with the empty vector or in the IRF-1-and IRF-2-expressing cells, were superimposable ( Figure 5A ), indicating that IRF-1 did not affect the growth rate of myeloid cells. This conclusion was supported by analysis of the expression of the cyclin-dependent kinase inhibitor p27 kip" ( Figure 5B ). Total cell extracts from 32D\RcCMV and 32D\IRF-1 cells treated with G-CSF were subjected to immunoblot analysis for p27 kip" . G-CSF induced an increase in p27 kip" expression as described previously [29] but no changes in p27 kip" or p21 waf levels (results not shown) were observed in IRF-1-expressing cells.
Accelerated c-Myb down-modulation and PU.1 stimulation in IRF-1-expressing cells
Down-regulation of c-Myb protein levels by expression of an antisense c-Myb construct was previously shown to accelerate 32Dcl3 granulocytic differentiation [30] . Furthermore, an IRF consensus sequence responsive to IRF-1 was detected in the human c-myb intron 1, a region involved in transcriptional pausing of the gene [31] . To investigate whether the ability of IRF-1 to potentiate terminal granulocytic differentiation involves c-Myb regulation, control and IRF-1-expressing 32Dcl3 cells were analysed for c-Myb expression at different times after G-CSF treatment. As shown in Figure 6 , cells constitutively expressing IRF-1 displayed a complete down-modulation of cMyb expression, whereas in control cells a decrease in the expressed c-Myb levels was only observed after 24 h of G-CSF treatment. Down-modulation of c-Myb in 32Dcl3 cells has also been associated with the ability of PU.1 to potentiate terminal myeloid differentiation [30] . To test whether the inhibitory effect of IRF-1 on c-Myb expression correlated with PU.1 stimulation, immunoblot analysis with the same cell extracts was performed using an anti-PU.1 polyclonal antibody. The results clearly indicated that a substantial increase (20-fold) in PU.1 expression was obtained in G-CSF-treated IRF-1-expressing cells as compared with control cells (3-fold) . These results suggest that IRF- were then processed for CAT activity. The results were quantified and expressed as described in the Materials and methods section. MeanspS.E.M. from three separate experiments were calculated after normalization with β-galactosidase activity as described in the Materials and methods section. SBE, signal transducers and activators of transcription (STAT) binding element.
1's down-modulation of c-Myb expression directly involves a mechanism of transcriptional pausing [31] . In addition the overexpression of PU.1 observed in 32D\IRF-1 cells may lead to a further inhibition of c-Myb as already described [30] .
IRF-1 binding and activation of the lysozyme promoter
Several IRF-1 gene targets involved in the antiviral and cellcycle-control activities of interferons have been recognized, whereas specific genes controlling the differentiated phenotype have not been investigated. Previous results, shown in Figures 3  and 4 , indicated a correlation between IRF-1 expression and induction of lysozyme and lactoferrin expression. By computerassisted analysis, we identified putative IRF-binding sites within the lysozyme promoter. To determine whether IRF-1 effectively binds to these sites, EMSA was performed using the radiolabelled oligonucleotide spanning nt k247 to k269 and in itrotranslated IRF-1 protein. As shown in Figure 7 a distinct protein-DNA complex was formed and supershifted with specific anti-IRF-1 antibody. Cells were also transiently co-transfected with a lysozyme promoter-CAT reporter construct spanning nt k527 to j9 and an IRF-1 expression vector. A 4-fold induction of CAT activity was observed in IRF-1-transfected cells even in the absence of G-CSF. This increase was comparable with that obtained in G-CSF-treated cells.
DISCUSSION
Differentiation of haematopoietic pluripotent stem cells consists of the progressive acquisition of a mature phenotype through transcription-factor-induced activation and repression of specific differentiation programmes (for a review see [2] ). Granulocytes arise from the bipotent colony-forming-unit granulocyte\ macrophage progenitors that can also differentiate into monocytes. C\EBPα has been identified as a master gene able to determine the switch to granulocyte lineage differentiation, and similarly IRF-8 has been implicated in progenitor lineage selection and monocyte maturation. In the present study we identified another member of the IRF family, IRF-1, as essential for granulocytic differentiation. Although IRF-1 does not completely replace the requirement for cytokines, inhibition of IRF-1 activity by overexpression of its functional antagonist IRF-2 completely abolished the differentiation process in 32Dcl3 cells.
Members of the IRF family of transcription factors have been widely implicated in innate and adaptive immune responses, and are regulated by immunomodulatory cytokines. It is thus likely that, in addition to antiviral responses, some members of the IRF family participate in the developmental regulation of cells of the immune system. In this respect IRF-1 −/− mice carry lineagespecific defects in thymocyte development and in T-cell selection and maturation ; it has been suggested that IRF-1 may regulate the expression of genes in developing thymocytes, which are required for lineage commitment and selection of CD8 + thymocytes [17, 32] . Similar defects in NK development and functionality have also been reported [16] .
An involvement of IRF-1 in myeloid differentiation has also been suggested [33, 34] and this study represents the first demonstration of an essential role of IRF-1 in neutrophilic differentiation. Two lines of evidence support this conclusion : (i) IRF-1-overexpressing 32Dcl3 cells, surviving growth-factor deprivation, undergo spontaneous granulocytic maturation ; and (ii) IRF-1 overexpression, on the other hand, potentiates granulocytic differentiation of 32Dcl3 cells in response to G-CSF. In 32Dcl3 cells expressing IRF-1, in fact, the kinetics of granulocytic differentiation were faster than for parental cells, and IRF-1-expressing cells fully differentiated as early as 4-5 days after G-CSF stimulation. This result is also in line with the data showing that the G-CSF-induced differentiation process was accompanied by a sustained increased expression of IRF-1, whereas in growing undifferentiated 32Dcl3 cells, IRF-1 expression was barely detectable ( Figure 1A ). More importantly this increase was also observed, beginning at day 2 of cultivation, in normal haematopoietic CD34 + progenitors allowed to differentiate into neutrophils ( Figure 1B ). Sustained expression of IRF-1 is suggestive of a requirement for IRF-1 in gene transcription in the late phase of differentiation. Accordingly, we show that IRF-1 directly binds and transactivates the lysozyme promoter ( Figure 7) .
In addition to this direct effect on the stimulation of differentiation markers, we show that IRF-1 is able to down-regulate genes involved in maintaining cells in an undifferentiated state. Indeed treatment of 32D\IRF-1 cells with G-CSF was associated with a decrease in c-Myb expression with kinetics faster than those observed in parental cells. Down-modulation of c-Myb expression is crucial for terminal differentiation [30, 35] . A primary mode of regulation of the gene [35] is transcriptional pausing in the first intron, where an IRF consensus sequence has been recently detected and expression of a reporter gene driven by this portion of the c-Myb promoter was directly suppressed by IRF-1 [31] . Thus in association with IRF-1-dependent differentiation-related mechanisms, IRF-1 also acts as a repressor of c-Myb transcription. The observation of negative regulation of c-Myb by IRF-1 is also consistent with the temporal pattern of expression of the two genes. c-Myb is expressed in precursor cells and its expression decreases as cells differentiate [36] , whereas IRF-1 is poorly expressed in CD34 + cells but highly expressed in fully differentiated granulocytes.
We have also showed that in IRF-1-expressing 32Dcl3 cells an increased expression of the Ets family member PU.1 occurs. PU.1 is essential for myeloid differentiation and potentiates terminal differentiation through a down-modulation of c-Myb [30] . Together, these results indicate that IRF-1 acts at several steps during granulocytic maturation, acting directly on genes such as lysozyme and c-myb and also indirectly through the stimulation of other transcription factors such as PU.1, which in turn acts on other differentiation markers such as CD11b.
Although IRF-1 can potentially affect 32Dcl3 cell growth, we surprisingly did not observe any specific effect of ectopic IRF-1 expression on the growth characteristics of 32Dcl3 cells in medium supplemented with IL-3 (results not shown) or G-CSF ( Figure  5A ). This result is supported by the data on p27 kip" (Figure 5B ), which indicate that no specific stimulation of p27 kip" in IRF-1-expressing cells occurs. So far, the role of IRF-1 in cell-cycle regulation and apoptosis has been established in fibroblasts and T-lymphocytes. In haematopoietic cells an involvement of IRF-1 in growth control was suggested on the basis of the observation that IRF-1 is deleted or shows exon skipping in acute promyelocytic leukaemia or leukaemias with a deletion of chromosome 5q31 [37] . However, recently, Guzman et al. [38] demonstrated that IRF-1 and DAPK (death-associated protein kinase), which are both recognized tumour-suppressor genes, were overexpressed in CD34 + \38 − cells derived from seven acute myeloid leukaemia patients. These results support the conclusion that IRF-1 selectively modulates different sets of genes depending on the cell type, the state of the cell and\or the nature of the stimuli, to evoke appropriate responses in each [13] .
Another striking result from this study is the complete repression of G-CSF-induced differentiation in IRF-2-expressing 32Dcl3 cells. In these cells, membrane expression of differentiation markers as well as granulocyte functional gene expression are expressed at levels even lower than that observed in parental cells, even in the presence of G-CSF. This result demonstrates the indispensable role of IRF-1 in granulocytic differentiation and raises the question of whether the effects of IRF-2 expression can all be ascribed to the inhibition of IRF-1-transcriptional activity. In fact, studies in IRF-2-knockout mice revealed generalized alteration in bone marrow haematopoiesis with a severe decrease in B-cell colony formation and a partial reduction in multipotent progenitors, pre-B-cells and also macrophage precursors. IRF-2 is generally considered the functional antagonist of IRF-1, able to selectively suppress IRF-1 transcriptional stimulation on most of the target genes examined. However, IRF-2 −/− mice, similarly to IRF-1 −/− mice, were shown recently to carry defects in NK development and\or function [39] , although the underlying mechanisms differ. How IRF-2 contributes to these phenomena is currently unknown. To this end the definition of additional specific gene targets of IRF-1 and IRF-2 in different cell systems evoking a variety of cellular responses is crucial.
